Deutsche Bank AG Reduces Position in Pediatrix Medical Group, Inc. $MD

Deutsche Bank AG lowered its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 9.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 67,025 shares of the company’s stock after selling 6,998 shares during the period. Deutsche Bank AG owned 0.08% of Pediatrix Medical Group worth $971,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. GAMMA Investing LLC grew its holdings in shares of Pediatrix Medical Group by 219.5% during the first quarter. GAMMA Investing LLC now owns 2,569 shares of the company’s stock valued at $37,000 after buying an additional 1,765 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in Pediatrix Medical Group by 218.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,445 shares of the company’s stock worth $98,000 after acquiring an additional 5,104 shares during the period. Squarepoint Ops LLC purchased a new stake in Pediatrix Medical Group during the 4th quarter valued at about $132,000. Sherbrooke Park Advisers LLC acquired a new position in shares of Pediatrix Medical Group in the fourth quarter valued at about $136,000. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Pediatrix Medical Group in the first quarter valued at about $159,000. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on MD shares. Zacks Research raised Pediatrix Medical Group to a “strong-buy” rating in a report on Monday, August 11th. Macquarie increased their price target on shares of Pediatrix Medical Group from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Thursday, May 8th. Finally, UBS Group lifted their price objective on shares of Pediatrix Medical Group from $16.00 to $16.50 and gave the company a “neutral” rating in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.75.

Pediatrix Medical Group Stock Up 5.1%

Shares of MD stock opened at $16.9730 on Monday. Pediatrix Medical Group, Inc. has a twelve month low of $10.06 and a twelve month high of $17.67. The stock has a market cap of $1.48 billion, a P/E ratio of 13.16 and a beta of 1.21. The stock has a 50 day moving average of $13.76 and a 200 day moving average of $13.94. The company has a current ratio of 1.80, a quick ratio of 1.80 and a debt-to-equity ratio of 0.70.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.11. The business had revenue of $468.84 million for the quarter, compared to analysts’ expectations of $464.37 million. Pediatrix Medical Group had a net margin of 5.66% and a return on equity of 18.94%. The business’s revenue was down 7.1% on a year-over-year basis. During the same quarter last year, the company earned $0.34 EPS. As a group, sell-side analysts expect that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.